Expands manufacturing push & locks in major growth deals
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Supported by Plan International, the partnership will help treat over 1,000 children annually
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance
Subscribe To Our Newsletter & Stay Updated
